Comparison of two proton pump inhibitor therapy approaches for laryngopharyngeal reflux disease treatment

The comparative study of symptom improvement according to proton pump inhibitor therapy approaches in laryngopharyngeal reflux disease patient

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004871

Enrollment

Registered

2020-04-02

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The effects of each oral therapy approaches (Ilaprazole 20mg once daily or 10mg twice daily) are compared by using reflux symptom index (RSI), reflux finding score (RFS), depression and anxiety

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients over 18 year (2) Those with above 13 and 7 score in reflux symptom index and reflux finding score and have laryngopharyngeal reflux disease in larynx endoscope (3) Patients who agree to participate in this study voluntarily

Exclusion criteria

Exclusion criteria: (1) The highly sensitive person to proton pump inhibitor (2) Those with the malignant tumor or infection of the larynx (3) Those with need to take steroids or aspirin (more than 325mg/d), warfarin, coumarin during this study constantly (4) Those who has undergone surgery or treatment for gastroesophageal reflux disease (5) Those who has undergone gastric acid suppression surgery or gastro-duodenal surgery (6) Those who has undergone major surgery affecting gastric acid secretion (7) Those with the history of administration with other proton pump inhibitor or H2-blocker within 3 months (8) Psychiatric patient, alcohol addictor or those with the history of drug abuse (9) Pregnant and lactating women (10) Childbearing women (Menopausal women who are amenorrheic for at least 12 months are considered to be non-childbearing women.) (11) Those who participated in other clinical trial within 6 months before screening (12) Those who are judged to be improper for this clinical trial

Design outcomes

Primary

Measure	Time frame
Reflux symptom index;Reflux finding score	—

Secondary

Measure	Time frame
Hospital anxiety and depression (HAD)	—

Countries

Korea, Republic of

Contacts

Public ContactIlseok Park

Hallym University Medical Center-Dongtan

Outcome results